Letter to the editor: 1-year clinical outcomes of bivalirudin vs. unfractionated heparin in patients with type 2 diabetes undergoing elective percutaneous coronary intervention

MeSH terms

• Anticoagulants / administration & dosage
• Anticoagulants / adverse effects
• Anticoagulants / therapeutic use
• Antithrombins* / administration & dosage
• Antithrombins* / adverse effects
• Antithrombins* / therapeutic use
• Coronary Artery Disease / diagnosis
• Coronary Artery Disease / mortality
• Coronary Artery Disease / therapy
• Diabetes Mellitus, Type 2* / blood
• Diabetes Mellitus, Type 2* / diagnosis
• Diabetes Mellitus, Type 2* / drug therapy
• Heparin* / administration & dosage
• Heparin* / adverse effects
• Heparin* / therapeutic use
• Hirudins* / administration & dosage
• Hirudins* / adverse effects
• Humans
• Peptide Fragments* / adverse effects
• Peptide Fragments* / therapeutic use
• Percutaneous Coronary Intervention* / adverse effects
• Percutaneous Coronary Intervention* / mortality
• Recombinant Proteins* / administration & dosage
• Recombinant Proteins* / adverse effects
• Recombinant Proteins* / therapeutic use
• Treatment Outcome